Lipoprotein-associated phospholipase A2: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
 
m (→‎Further reading: task, replaced: Stroke; A Journal of Cerebral Circulation → Stroke: A Journal of Cerebral Circulation using AWB)
Line 1: Line 1:
#Redirect[[Lipoprotein-associated phospholipase A2 (Lp-PLA2)]]
{{Infobox_gene}}
 
'''Lipoprotein-associated [[phospholipase A2]]''' ('''Lp-PLA2''') also known as '''platelet-activating factor acetylhydrolase''' ('''PAF-AH''') is a [[phospholipase A2]] [[enzyme]] that in humans is encoded by the ''PLA2G7'' [[gene]].<ref name="pmid7700381">{{cite journal | vauthors = Tjoelker LW, Wilder C, Eberhardt C, Stafforini DM, Dietsch G, Schimpf B, Hooper S, Le Trong H, Cousens LS, Zimmerman GA, Yamada Y, McIntyre TM, Prescott SM, Gray PW | title = Anti-inflammatory properties of a platelet-activating factor acetylhydrolase | journal = Nature | volume = 374 | issue = 6522 | pages = 549–53 | date = Apr 1995 | pmid = 7700381 | doi = 10.1038/374549a0 }}</ref><ref name="pmid8624782">{{cite journal | vauthors = Tew DG, Southan C, Rice SQ, Lawrence MP, Li H, Boyd HF, Moores K, Gloger IS, Macphee CH | title = Purification, properties, sequencing, and cloning of a lipoprotein-associated, serine-dependent phospholipase involved in the oxidative modification of low-density lipoproteins | journal = Arteriosclerosis, Thrombosis, and Vascular Biology | volume = 16 | issue = 4 | pages = 591–9 | date = Apr 1996 | pmid = 8624782 | doi = 10.1161/01.ATV.16.4.591 }}</ref> Lp-PLA<sub>2</sub> is a 45-kDa [[protein]] of 441 [[amino acid]]s.<ref name="Zalewski_2005">{{cite journal | vauthors = Zalewski A, Macphee C | title = Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target | journal = Arteriosclerosis, Thrombosis, and Vascular Biology | volume = 25 | issue = 5 | pages = 923–31 | date = May 2005 | pmid = 15731492 | doi = 10.1161/01.ATV.0000160551.21962.a7 }}</ref> It is one of several [[PAF acetylhydrolase]]s.
 
== Function ==
 
In the blood it travels mainly with [[low-density lipoprotein]] (LDL). Less than 20% is associated with [[high-density lipoprotein]] HDL. It is an enzyme produced by [[inflammatory cell]]s and hydrolyzes oxidized [[phospholipid]]s in LDL.
 
Lp-PLA<sub>2</sub> is platelet-activating factor ([[platelet-activating factor|PAF]]) acetylhydrolase (EC 3.1.1.47), a secreted enzyme that catalyzes the degradation of PAF to inactive products by hydrolysis of the acetyl group at the sn-2 position, producing the biologically inactive products LYSO-PAF and acetate.<ref name="entrez">{{cite web | title = Entrez Gene: PLA2G7 phospholipase A2, group VII (platelet-activating factor acetylhydrolase, plasma)| url = https://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=7941| accessdate = }}</ref>
 
== Clinical significance ==
 
Lp-PLA<sub>2</sub> is involved in the development of [[atherosclerosis]],<ref name="Zalewski_2005"/> an observation that has prompted interest as a possible therapeutic target (see, e.g. the investigational drug [[Darapladib]]). In human atherosclerotic lesions, 2 main sources of Lp-PLA<sub>2</sub> can be identified, including that which is brought into the [[intima]] bound to LDL (from the circulation), and that which is synthesized de novo by plaque inflammatory cells ([[macrophage]]s, T cells, mast cells)."
 
It is used as a marker for cardiac disease.<ref name="pmid18436114">{{cite journal | vauthors = Mohler ER, Ballantyne CM, Davidson MH, Hanefeld M, Ruilope LM, Johnson JL, Zalewski A | title = The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study | journal = Journal of the American College of Cardiology | volume = 51 | issue = 17 | pages = 1632–41 | date = Apr 2008 | pmid = 18436114 | doi = 10.1016/j.jacc.2007.11.079 }}</ref>
 
A [[meta-analysis]] involving a total of 79,036 participants in 32 prospective studies found that Lp-PLA<sub>2</sub> levels are positively correlated with increased risk of developing [[coronary heart disease]] and [[stroke]].<ref name="The Lp-PLA2 Studies Collaboration">{{ cite journal | author = The Lp-PLA<sub>2</sub> Studies Collaboration | year = 2010 | title = Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies | journal = The Lancet | volume = 375 | issue = 9725 | pages = 1536–1544 | doi = 10.1016/S0140-6736(10)60319-4 | laysummary = http://news.bbc.co.uk/2/hi/health/8652005.stm | laysource = BBC News | pmid=20435228 | pmc=2864403}}</ref>
 
== See also ==
*[[darapladib]]
 
== References ==
{{reflist}}
 
== Further reading ==
{{refbegin | 2}}
* {{cite journal | vauthors = Schröder HC, Perovic S, Kavsan V, Ushijima H, Müller WE | title = Mechanisms of prionSc- and HIV-1 gp120 induced neuronal cell death | journal = Neurotoxicology | volume = 19 | issue = 4–5 | pages = 683–8 | year = 1998 | pmid = 9745929 | doi =  }}
* {{cite journal | vauthors = Feng Y, Walsh CA | title = Protein-protein interactions, cytoskeletal regulation and neuronal migration | journal = Nature Reviews. Neuroscience | volume = 2 | issue = 6 | pages = 408–16 | date = Jun 2001 | pmid = 11389474 | doi = 10.1038/35077559 }}
* {{cite journal | vauthors = Tjoelker LW, Eberhardt C, Unger J, Trong HL, Zimmerman GA, McIntyre TM, Stafforini DM, Prescott SM, Gray PW | title = Plasma platelet-activating factor acetylhydrolase is a secreted phospholipase A2 with a catalytic triad | journal = The Journal of Biological Chemistry | volume = 270 | issue = 43 | pages = 25481–7 | date = Oct 1995 | pmid = 7592717 | doi = 10.1074/jbc.270.43.25481 }}
* {{cite journal | vauthors = Stafforini DM, Satoh K, Atkinson DL, Tjoelker LW, Eberhardt C, Yoshida H, Imaizumi T, Takamatsu S, Zimmerman GA, McIntyre TM, Gray PW, Prescott SM | title = Platelet-activating factor acetylhydrolase deficiency. A missense mutation near the active site of an anti-inflammatory phospholipase | journal = The Journal of Clinical Investigation | volume = 97 | issue = 12 | pages = 2784–91 | date = Jun 1996 | pmid = 8675689 | pmc = 507371 | doi = 10.1172/JCI118733 }}
* {{cite journal | vauthors = Yamada Y, Yokota M | title = Loss of activity of plasma platelet-activating factor acetylhydrolase due to a novel Gln281-->Arg mutation | journal = Biochemical and Biophysical Research Communications | volume = 236 | issue = 3 | pages = 772–5 | date = Jul 1997 | pmid = 9245731 | doi = 10.1006/bbrc.1997.7047 }}
* {{cite journal | vauthors = Mavoungou E, Georges-Courbot MC, Poaty-Mavoungou V, Nguyen HT, Yaba P, Delicat A, Georges AJ, Russo-Marie F | title = HIV and SIV envelope glycoproteins induce phospholipase A2 activation in human and macaque lymphocytes | journal = Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology | volume = 16 | issue = 1 | pages = 1–9 | date = Sep 1997 | pmid = 9377118 | doi = 10.1097/00042560-199709010-00001 }}
* {{cite journal | vauthors = Sapir T, Elbaum M, Reiner O | title = Reduction of microtubule catastrophe events by LIS1, platelet-activating factor acetylhydrolase subunit | journal = The EMBO Journal | volume = 16 | issue = 23 | pages = 6977–84 | date = Dec 1997 | pmid = 9384577 | pmc = 1170301 | doi = 10.1093/emboj/16.23.6977 }}
* {{cite journal | vauthors = Hiramoto M, Yoshida H, Imaizumi T, Yoshimizu N, Satoh K | title = A mutation in plasma platelet-activating factor acetylhydrolase (Val279-->Phe) is a genetic risk factor for stroke | journal = Stroke: A Journal of Cerebral Circulation | volume = 28 | issue = 12 | pages = 2417–20 | date = Dec 1997 | pmid = 9412624 | doi = 10.1161/01.str.28.12.2417 }}
* {{cite journal | vauthors = Yamada Y, Ichihara S, Fujimura T, Yokota M | title = Identification of the G994--> T missense in exon 9 of the plasma platelet-activating factor acetylhydrolase gene as an independent risk factor for coronary artery disease in Japanese men | journal = Metabolism | volume = 47 | issue = 2 | pages = 177–81 | date = Feb 1998 | pmid = 9472966 | doi = 10.1016/S0026-0495(98)90216-5 }}
* {{cite journal | vauthors = Yoshida H, Imaizumi T, Fujimoto K, Itaya H, Hiramoto M, Yoshimizu N, Fukushi K, Satoh K | title = A mutation in plasma platelet-activating factor acetylhydrolase (Val279Phe) is a genetic risk factor for cerebral hemorrhage but not for hypertension | journal = Thrombosis and Haemostasis | volume = 80 | issue = 3 | pages = 372–5 | date = Sep 1998 | pmid = 9759612 | doi =  }}
* {{cite journal | vauthors = Lecointe N, Meerabux J, Ebihara M, Hill A, Young BD | title = Molecular analysis of an unstable genomic region at chromosome band 11q23 reveals a disruption of the gene encoding the alpha2 subunit of platelet-activating factor acetylhydrolase (Pafah1a2) in human lymphoma | journal = Oncogene | volume = 18 | issue = 18 | pages = 2852–9 | date = May 1999 | pmid = 10362256 | doi = 10.1038/sj.onc.1202645 }}
* {{cite journal | vauthors = Kruse S, Mao XQ, Heinzmann A, Blattmann S, Roberts MH, Braun S, Gao PS, Forster J, Kuehr J, Hopkin JM, Shirakawa T, Deichmann KA | title = The Ile198Thr and Ala379Val variants of plasmatic PAF-acetylhydrolase impair catalytical activities and are associated with atopy and asthma | journal = American Journal of Human Genetics | volume = 66 | issue = 5 | pages = 1522–30 | date = May 2000 | pmid = 10733466 | pmc = 1378003 | doi = 10.1086/302901 }}
* {{cite journal | vauthors = Howard KM, Olson MS | title = The expression and localization of plasma platelet-activating factor acetylhydrolase in endotoxemic rats | journal = The Journal of Biological Chemistry | volume = 275 | issue = 26 | pages = 19891–6 | date = Jun 2000 | pmid = 10748027 | doi = 10.1074/jbc.M001462200 }}
* {{cite journal | vauthors = Min JH, Wilder C, Aoki J, Arai H, Inoue K, Paul L, Gelb MH | title = Platelet-activating factor acetylhydrolases: broad substrate specificity and lipoprotein binding does not modulate the catalytic properties of the plasma enzyme | journal = Biochemistry | volume = 40 | issue = 15 | pages = 4539–49 | date = Apr 2001 | pmid = 11294621 | doi = 10.1021/bi002600g }}
* {{cite journal | vauthors = Quarck R, De Geest B, Stengel D, Mertens A, Lox M, Theilmeier G, Michiels C, Raes M, Bult H, Collen D, Van Veldhoven P, Ninio E, Holvoet P | title = Adenovirus-mediated gene transfer of human platelet-activating factor-acetylhydrolase prevents injury-induced neointima formation and reduces spontaneous atherosclerosis in apolipoprotein E-deficient mice | journal = Circulation | volume = 103 | issue = 20 | pages = 2495–500 | date = May 2001 | pmid = 11369691 | doi = 10.1161/01.cir.103.20.2495 }}
* {{cite journal | vauthors = Unno N, Nakamura T, Mitsuoka H, Uchiyama T, Yamamoto N, Saito T, Sugatani J, Miwa M, Nakamura S | title = Association of a G994 -->T missense mutation in the plasma platelet-activating factor acetylhydrolase gene with risk of abdominal aortic aneurysm in Japanese | journal = Annals of Surgery | volume = 235 | issue = 2 | pages = 297–302 | date = Feb 2002 | pmid = 11807372 | pmc = 1422429 | doi = 10.1097/00000658-200202000-00020 }}
{{refend}}
 
{{PAF signaling}}
 
[[Category:Proteins]]

Revision as of 01:18, 16 November 2017

VALUE_ERROR (nil)
Identifiers
Aliases
External IDsGeneCards: [1]
Orthologs
SpeciesHumanMouse
Entrez

n/a

n/a

Ensembl

n/a

n/a

UniProt

n/a

n/a

RefSeq (mRNA)

n/a

n/a

RefSeq (protein)

n/a

n/a

Location (UCSC)n/an/a
PubMed searchn/an/a
Wikidata
View/Edit Human

Lipoprotein-associated phospholipase A2 (Lp-PLA2) also known as platelet-activating factor acetylhydrolase (PAF-AH) is a phospholipase A2 enzyme that in humans is encoded by the PLA2G7 gene.[1][2] Lp-PLA2 is a 45-kDa protein of 441 amino acids.[3] It is one of several PAF acetylhydrolases.

Function

In the blood it travels mainly with low-density lipoprotein (LDL). Less than 20% is associated with high-density lipoprotein HDL. It is an enzyme produced by inflammatory cells and hydrolyzes oxidized phospholipids in LDL.

Lp-PLA2 is platelet-activating factor (PAF) acetylhydrolase (EC 3.1.1.47), a secreted enzyme that catalyzes the degradation of PAF to inactive products by hydrolysis of the acetyl group at the sn-2 position, producing the biologically inactive products LYSO-PAF and acetate.[4]

Clinical significance

Lp-PLA2 is involved in the development of atherosclerosis,[3] an observation that has prompted interest as a possible therapeutic target (see, e.g. the investigational drug Darapladib). In human atherosclerotic lesions, 2 main sources of Lp-PLA2 can be identified, including that which is brought into the intima bound to LDL (from the circulation), and that which is synthesized de novo by plaque inflammatory cells (macrophages, T cells, mast cells)."

It is used as a marker for cardiac disease.[5]

A meta-analysis involving a total of 79,036 participants in 32 prospective studies found that Lp-PLA2 levels are positively correlated with increased risk of developing coronary heart disease and stroke.[6]

See also

References

  1. ↑ Tjoelker LW, Wilder C, Eberhardt C, Stafforini DM, Dietsch G, Schimpf B, Hooper S, Le Trong H, Cousens LS, Zimmerman GA, Yamada Y, McIntyre TM, Prescott SM, Gray PW (Apr 1995). "Anti-inflammatory properties of a platelet-activating factor acetylhydrolase". Nature. 374 (6522): 549–53. doi:10.1038/374549a0. PMID 7700381.
  2. ↑ Tew DG, Southan C, Rice SQ, Lawrence MP, Li H, Boyd HF, Moores K, Gloger IS, Macphee CH (Apr 1996). "Purification, properties, sequencing, and cloning of a lipoprotein-associated, serine-dependent phospholipase involved in the oxidative modification of low-density lipoproteins". Arteriosclerosis, Thrombosis, and Vascular Biology. 16 (4): 591–9. doi:10.1161/01.ATV.16.4.591. PMID 8624782.
  3. ↑ 3.0 3.1 Zalewski A, Macphee C (May 2005). "Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target". Arteriosclerosis, Thrombosis, and Vascular Biology. 25 (5): 923–31. doi:10.1161/01.ATV.0000160551.21962.a7. PMID 15731492.
  4. ↑ "Entrez Gene: PLA2G7 phospholipase A2, group VII (platelet-activating factor acetylhydrolase, plasma)".
  5. ↑ Mohler ER, Ballantyne CM, Davidson MH, Hanefeld M, Ruilope LM, Johnson JL, Zalewski A (Apr 2008). "The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study". Journal of the American College of Cardiology. 51 (17): 1632–41. doi:10.1016/j.jacc.2007.11.079. PMID 18436114.
  6. ↑ The Lp-PLA2 Studies Collaboration (2010). "Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies". The Lancet. 375 (9725): 1536–1544. doi:10.1016/S0140-6736(10)60319-4. PMC 2864403. PMID 20435228. Lay summary – BBC News.

Further reading

Retrieved from "https://www.wikidoc.org/index.php?title=Lipoprotein-associated_phospholipase_A2&oldid=1421335"